Comparative efficacy of five approved Janus kinase inhibitors as monotherapy and combination therapy in patients with moderate-to-severe active rheumatoid arthritis: a systematic review and network meta-analysis of randomized controlled trials
BackgroundThe European League of Rheumatology(EULAR)guidelines recommend Janus kinase (JAK) inhibitors for patients with moderate to severe rheumatoid arthritis (RA) who are insensitive or under-responsive to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). But there was no...
Saved in:
Main Authors: | Wenting Cai (Author), Rui Tong (Author), Yue Sun (Author), Yao Yao (Author), Jinping Zhang (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
by: Vishal R. Tandon, et al.
Published: (2022) -
Effectiveness of Janus kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis
by: A. E. Cheberda, et al.
Published: (2024) -
Epigenetic targets of Janus kinase inhibitors are linked to genetic risks of rheumatoid arthritis
by: Haruka Tsuchiya, et al.
Published: (2024) -
Potential Adverse Events Reported With the Janus Kinase Inhibitors Approved for the Treatment of Rheumatoid Arthritis Using Spontaneous Reports and Online Patient Reviews
by: Yun-Kyoung Song, et al.
Published: (2022) -
Systematic review of Janus kinases inhibitors for rheumatoid arthritis: methodology, reporting, and quality of evidence evaluation
by: Xiaolan Shen, et al.
Published: (2024)